LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance

    Martin Schröder / Martin Renatus / Xiaoyou Liang / Fabian Meili / Thomas Zoller / Sandrine Ferrand / Francois Gauter / Xiaoyan Li / Frederic Sigoillot / Scott Gleim / Therese-Marie Stachyra / Jason R. Thomas / Damien Begue / Maryam Khoshouei / Peggy Lefeuvre / Rita Andraos-Rey / BoYee Chung / Renate Ma / Benika Pinch /
    Andreas Hofmann / Markus Schirle / Niko Schmiedeberg / Patricia Imbach / Delphine Gorses / Keith Calkins / Beatrice Bauer-Probst / Magdalena Maschlej / Matt Niederst / Rob Maher / Martin Henault / John Alford / Erik Ahrne / Luca Tordella / Greg Hollingworth / Nicolas H. Thomä / Anna Vulpetti / Thomas Radimerski / Philipp Holzer / Seth Carbonneau / Claudio R. Thoma

    Nature Communications, Vol 15, Iss 1, Pp 1-

    2024  Volume 19

    Abstract: Abstract Targeted protein degradation (TPD) mediates protein level through small molecule induced redirection of E3 ligases to ubiquitinate neo-substrates and mark them for proteasomal degradation. TPD has recently emerged as a key modality in drug ... ...

    Abstract Abstract Targeted protein degradation (TPD) mediates protein level through small molecule induced redirection of E3 ligases to ubiquitinate neo-substrates and mark them for proteasomal degradation. TPD has recently emerged as a key modality in drug discovery. So far only a few ligases have been utilized for TPD. Interestingly, the workhorse ligase CRBN has been observed to be downregulated in settings of resistance to immunomodulatory inhibitory drugs (IMiDs). Here we show that the essential E3 ligase receptor DCAF1 can be harnessed for TPD utilizing a selective, non-covalent DCAF1 binder. We confirm that this binder can be functionalized into an efficient DCAF1-BRD9 PROTAC. Chemical and genetic rescue experiments validate specific degradation via the CRL4DCAF1 E3 ligase. Additionally, a dasatinib-based DCAF1 PROTAC successfully degrades cytosolic and membrane-bound tyrosine kinases. A potent and selective DCAF1-BTK-PROTAC (DBt-10) degrades BTK in cells with acquired resistance to CRBN-BTK-PROTACs while the DCAF1-BRD9 PROTAC (DBr-1) provides an alternative strategy to tackle intrinsic resistance to VHL-degrader, highlighting DCAF1-PROTACS as a promising strategy to overcome ligase mediated resistance in clinical settings.
    Keywords Science ; Q
    Subject code 571
    Language English
    Publishing date 2024-01-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  2. Article ; Online: Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells

    Shingo Kozono / Yu-Min Lin / Hyuk-Soo Seo / Benika Pinch / Xiaolan Lian / Chenxi Qiu / Megan K. Herbert / Chun-Hau Chen / Li Tan / Ziang Jeff Gao / Walter Massefski / Zainab M. Doctor / Brian P. Jackson / Yuanzhong Chen / Sirano Dhe-Paganon / Kun Ping Lu / Xiao Zhen Zhou

    Nature Communications, Vol 9, Iss 1, Pp 1-

    2018  Volume 17

    Abstract: Arsenic trioxide and all-trans retinoic acid combination safely cures human acute promyelocytic leukemia. Here, the authors show that this combination has potent anticancer activity in triple negative breast cancer by cooperatively targeting Pin1, a ... ...

    Abstract Arsenic trioxide and all-trans retinoic acid combination safely cures human acute promyelocytic leukemia. Here, the authors show that this combination has potent anticancer activity in triple negative breast cancer by cooperatively targeting Pin1, a master regulator of oncogenic signaling networks, to eliminate cancer stem cells.
    Keywords Science ; Q
    Language English
    Publishing date 2018-08-01T00:00:00Z
    Publisher Nature Publishing Group
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article ; Online: Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells

    Shingo Kozono / Yu-Min Lin / Hyuk-Soo Seo / Benika Pinch / Xiaolan Lian / Chenxi Qiu / Megan K. Herbert / Chun-Hau Chen / Li Tan / Ziang Jeff Gao / Walter Massefski / Zainab M. Doctor / Brian P. Jackson / Yuanzhong Chen / Sirano Dhe-Paganon / Kun Ping Lu / Xiao Zhen Zhou

    Nature Communications, Vol 9, Iss 1, Pp 1-

    2018  Volume 17

    Abstract: Arsenic trioxide and all-trans retinoic acid combination safely cures human acute promyelocytic leukemia. Here, the authors show that this combination has potent anticancer activity in triple negative breast cancer by cooperatively targeting Pin1, a ... ...

    Abstract Arsenic trioxide and all-trans retinoic acid combination safely cures human acute promyelocytic leukemia. Here, the authors show that this combination has potent anticancer activity in triple negative breast cancer by cooperatively targeting Pin1, a master regulator of oncogenic signaling networks, to eliminate cancer stem cells.
    Keywords Science ; Q
    Language English
    Publishing date 2018-08-01T00:00:00Z
    Publisher Nature Portfolio
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top